Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO - Get Free Report) saw unusually large options trading on Thursday. Investors purchased 58,638 put options on the company. This is an increase of 58% compared to the average volume of 37,048 put options.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Novare Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock worth $325,000 after acquiring an additional 85 shares during the period. Steel Grove Capital Advisors LLC boosted its stake in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after buying an additional 86 shares in the last quarter. Benjamin Edwards Inc. boosted its stake in Novo Nordisk A/S by 2.6% during the second quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company's stock worth $493,000 after buying an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton increased its holdings in Novo Nordisk A/S by 2.5% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock valued at $454,000 after buying an additional 94 shares during the period. Finally, Burns J W & Co. Inc. NY boosted its position in shares of Novo Nordisk A/S by 1.9% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company's stock valued at $647,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $140.20.

Novo Nordisk A/S Stock Performance

NVO traded up $0.37 during midday trading on Thursday, reaching $83.29. The company's stock had a trading volume of 4,922,901 shares, compared to its average volume of 7,928,817. Novo Nordisk A/S has a twelve month low of $80.05 and a twelve month high of $148.15. The stock has a market cap of $373.78 billion, a P/E ratio of 26.98, a PEG ratio of 0.92 and a beta of 0.45. The company has a fifty day simple moving average of $99.26 and a 200 day simple moving average of $118.18. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.